HOME >> BIOLOGY >> NEWS
Biogen Idec acquires Brandeis spin-out

WALTHAM, MassSyntonix Pharmaceuticals, a spin-out company formed by Brandeis University, Brigham and Women's Hospital, and Children's Hospital Boston announced today that it was acquired by biotech giant Biogen Idec (NASDAQ: BIIB - News). Syntonix, a privately held biopharmaceutical company, was founded in 1997 based on breakthrough discoveries from the laboratories of Neil Simister, Ph.D. (Brandeis), Wayne Lencer, M.D. (Children's), and Richard S. Blumberg, M.D. (Brigham). Their research harnesses the human body's natural immunological pathways for novel methods of drug delivery.

"We founded Syntonix with the hope of translating our basic discoveries into improvements in healthcare. The company developed and expanded our technologies to the stage where they have preclinical candidates for treating hemophilia and infertility. Biogen Idec's acquisition is an excellent outcome because they have the expertise in manufacturing and development to bring these drugs to the clinic," said Neil Simister, a Brandeis biology professor and one of Syntonix' founders.

"Brandeis University has a very strong science faculty. This acquisition by Biogen Idec is evidence of the strength of Brandeis' technology. Brandeis has spun-out a number of companies; however, this is the first to be acquired by a large biotech. We are very pleased to have Biogen Idec as our new licensee and we look forward to their success with this technology," said Irene Abrams, the Director of the Office of Technology Licensing at Brandeis University.

Syntonix's lead product, FIX:Fc, is a proprietary long-acting factor IX product for the treatment of hemophilia B. It has the potential to reduce the frequency of intravenous injections required for disease management. Syntonix is expected to file an investigational new drug application with the Food and Drug Administration for FIX:Fc in 2007.

The transaction closed on Januray 31, 2007. In connection with the closing of th
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
31-Jan-2007


Page: 1 2 3

Related biology news :

1. Macrochem acquires option to license pexiganan
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. New Brandeis research sheds light on memory by erasing it
10. National Academy of Sciences elects 2 Brandeis University scientists to membership
11. Brandeis and Brigham and Womens Hospital license technology for Gauchers to Amicus Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... 2020 , ... In an upcoming episode scheduled for the fall of 2020, ... solutions (POCT). Check local listings for more info. , Today, the majority of testing ... to labs throughout the country. Results are then available several days later. Now, in ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... and monoclonal antibody development services, today announced that the company has received ... to the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of large molecules or ... dominated this area. However, the use of mass spectrometry in this field has gained ... question “How do you choose which approach to use (LBA or MS)?” In ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... in the early detection and prevention of high-burden diseases, and Centric Consulting, a ... and healthcare organizations to utilize existing data in order to identify and prioritize ...
(Date:7/10/2020)... Mass. (PRWEB) , ... July 09, 2020 , ... ... approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., ... team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight ... microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, ...
Breaking Biology Technology:
Cached News: